Share

Pharmaceutical Companies Team Up to Develop Acromegaly Treatment

Two pharmaceutical companies will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical development as a potential treatment for acromegaly Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, and PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, today announced a research collaboration...
Share

Anorexia May Stunt Young Women’s Growth

Girls with anorexia nervosa can have stunted growth and may not reach their full height potential, according to a new study published in The Journal of Clinical Endocrinology & Metabolism. Anorexia nervosa is a condition in which a person loses an unhealthy amount of weight on purpose by dieting, sometimes along with excessive exercise, binge eating, and/or purging behaviors. People with anorexia nervosa have an intense fear of...
Share

FDA Approves Leuprolide Acetate for Injectable Suspension for Pediatric Patients with Central Precocious Puberty

The U.S. Food and Drug Administration (FDA) last month approved leuprolide acetate for injectable suspension for the treatment of pediatric patients two years of age and older with central precocious puberty (CPP). Tolmar Pharmaceuticals is marketing the drug as Fensolvi. Leuprolide acetate is the most widely used treatment for CPP. Fensolvi utilizes a proprietary polymeric gel...
Share

After Shocks: Complications after Acromegaly

Dr Castinetti A French study published in the Journal of the Endocrine Society reveals myriad complications that many acromegaly patients face after they’ve been successfully treated. Lead researcher Frederic Castinetti, MD, PhD, discusses his research and why follow-up may still be required once a patient is “cured.” Last December, a paper appeared in the Journal of the Endocrine Society...
Share

Researchers Find Slightly Elevated Cancer Incidence in Patients with Acromegaly

Cancer incidence rates are slightly elevated in patients with acromegaly, according to a meta-analysis recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Jens Otto Lunde Jørgensen, MD, DMSc, of the Department of Endocrinology and Internal Medicine at Aarhus University Hospital in Norrebrogade, Denmark point out that acromegaly has been associated...
Share

Differential Diagnoses Should Be Considered in Patients with Features of Acromegaly without Excess GH Secretion

JES_Cover_FINAL A paper published recently in the Journal of the Endocrine Society details a case of a woman with acromegaly-like features, but she did not have excess growth hormone (GH) secretion. The authors use the case to show that differential diagnoses should be considered in these patients with “pseudoacromegaly” or “acromegaloidism.” The paper, by Per Dahlqvist,...